Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes both composition and method claims related to the company’s proprietary approach to preventing or delaying stress-induced behavioral responses. This allowance follows a corresponding patent issued by the Japan Patent Office earlier this year.
A Notice of Allowance signifies that the USPTO has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly. This development is crucial for Silo Pharma as it advances SPC-15 through development, providing a layer of protection for its innovative treatment approach.
“The U.S. patent protection is an important component of our strategy as we advance SPC-15 development for PTSD,” said a representative of Silo Pharma. The patent adds to the company’s growing biopharmaceutical intellectual property portfolio of issued and allowed patents.
PTSD is a debilitating psychiatric disorder that affects millions of people worldwide, often arising after exposure to traumatic events. Current treatments may not be effective for all patients, underscoring the need for new therapeutic options. SPC-15’s intranasal delivery could offer a more convenient and rapid-onset alternative, potentially improving patient adherence and outcomes.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
For investors and industry observers, this patent allowance represents a significant milestone that could enhance the company’s valuation and competitive position in the neuropsychiatric space. It also signals progress in a challenging area of drug development where effective treatments are limited. The news may impact the broader biotech sector by highlighting the potential of intranasal therapies for CNS disorders and encouraging further investment in this niche.
To view the full press release, visit https://ibn.fm/Hh4Z6. The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO.
BioMedWire (BMW) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only). For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
